MNQ Chart Thread, page-302

Valid points M, I suspect these trials started well before MNQ came on the scene and Curtin would have had limited funding to increase the size of patients. For mine I think its not the quantity of the sample but more importantly the quality the product delivers to the targeted audience. I think the current SP reflects the uncertainty on the 3mill raising, once this is determined I do think MNQ will get its overdue rerate.